Last reviewed · How we verify
Anti-Influenza Vaccine
At a glance
| Generic name | Anti-Influenza Vaccine |
|---|---|
| Also known as | Flublok |
| Sponsor | Donald T. Weed, MD, FACS |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388 (PHASE2)
- Efficacy Safety Study of Flu Vaccine in Immunodepression Patients (PHASE3)
- Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. (PHASE4)
- Influenza Viral Challenge Study of CC-42344 in Healthy Participants (PHASE2)
- Tfh Dysfunction in HIV and Aging (PHASE4)
- Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Influenza Vaccine CI brief — competitive landscape report
- Anti-Influenza Vaccine updates RSS · CI watch RSS
- Donald T. Weed, MD, FACS portfolio CI